{"cells":[{"cell_type":"markdown","source":["<h1> DATAFRAME IMPLENENTATION</h1>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"02b5612b-1e8e-49bc-8e4a-f7d0e36a64b1"}}},{"cell_type":"markdown","source":["<h2> Import datasets</h2>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"96bf233c-ff3d-42a4-a71c-da4048bc5b6a"}}},{"cell_type":"code","source":["fileroot = \"clinicaltrial_2021.csv\"\nimport os\nos.environ['fileroot'] = fileroot\ndbutils.fs.cp(\"/FileStore/tables/\"+ fileroot + \".gz\", \"file:/tmp/\", True)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f9491223-1767-4dfe-94d9-bf862797d117"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[1]: True","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[1]: True"]}}],"execution_count":0},{"cell_type":"code","source":["%sh\ngunzip -d /tmp/ /tmp/$fileroot.gz"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"729c9dcf-4f4f-40e1-8617-75b3cdf93dbb"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"gzip: /tmp/ is a directory -- ignored\ngzip: /tmp/clinicaltrial_2021.csv already exists;\tnot overwritten\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["gzip: /tmp/ is a directory -- ignored\ngzip: /tmp/clinicaltrial_2021.csv already exists;\tnot overwritten\n"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.cp (\"file:/tmp/\" + fileroot , \"/FileStore/\" + fileroot, True)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"adf5a51c-3f42-4a4f-ae48-875571c7c1a3"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[3]: True","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[3]: True"]}}],"execution_count":0},{"cell_type":"code","source":["data = \"/FileStore/\"+ fileroot\n# Create an DF\nclinical_df = spark.read.options(header=True, delimiter='|').csv(data)\nclinical_df.show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7c7e2bc3-7283-4ca6-af06-535e6b489d93"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["fileroot_ = \"mesh\"\ndata = \"/FileStore/\"+ fileroot_ + \".csv\"\n# Create an RDD\nmesh_df = spark.read.options(header=True, delimiter=',').csv(data)\nmesh_df.show(5, False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e4387f7a-4c35-4198-9698-912e7d879abd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------+-------------------+\n|term      |tree               |\n+----------+-------------------+\n|Calcimycin|D03.633.100.221.173|\n|A-23187   |D03.633.100.221.173|\n|Temefos   |D02.705.400.625.800|\n|Temefos   |D02.705.539.345.800|\n|Temefos   |D02.886.300.692.800|\n+----------+-------------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------+-------------------+\n|term      |tree               |\n+----------+-------------------+\n|Calcimycin|D03.633.100.221.173|\n|A-23187   |D03.633.100.221.173|\n|Temefos   |D02.705.400.625.800|\n|Temefos   |D02.705.539.345.800|\n|Temefos   |D02.886.300.692.800|\n+----------+-------------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["fileroot_ = \"pharma\"\ndata = \"/FileStore/tables/\"+ fileroot_ + \".csv\"\n# Create an RDD\npharma_df = spark.read.options(header=True, delimiter=',').csv(data)\npharma_df.show(5, False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"73e767a8-c56e-4e16-8b64-31e623e9102a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Company                              |Parent_Company     |Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group                          |Primary_Offense                                      |Secondary_Offense       |Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Level_of_Government|Action_Type  |Agency                                                         |Civil/Criminal    |Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City    |Address|Zip |NAICS_Code|NAICS_Translation                                                                |HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source                                                                                                                   |Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Abbott Laboratories                  |Abbott Laboratories|$5,475,000    |$0                      |$5,475,000                                               |2013        |20131227    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery   |Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.                                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$1,500,000,000|$0                      |$1,500,000,000                                           |2012        |20120507    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                    |Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.|federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$126,500,000  |$0                      |$126,500,000                                             |2010        |20101207    |government-contracting-related offenses|False Claims Act and related                         |null                    |Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.                                                                                                                                                                                                                                                |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases                    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Puerto Rico, Inc.|Abbott Laboratories|$49,045       |$0                      |$49,045                                                  |2009        |20090305    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1527129|null                         |null              |Puerto Rico   |San Juan|null   |null|423450    |423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers|USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php|Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Acclarent Inc.                       |Johnson & Johnson  |$18,000,000   |$0                      |$18,000,000                                              |2016        |20160722    |government-contracting-related offenses|False Claims Act and related                         |null                    |California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.                                                                                                                                                                                                                                                    |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Company                              |Parent_Company     |Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group                          |Primary_Offense                                      |Secondary_Offense       |Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Level_of_Government|Action_Type  |Agency                                                         |Civil/Criminal    |Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City    |Address|Zip |NAICS_Code|NAICS_Translation                                                                |HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source                                                                                                                   |Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Abbott Laboratories                  |Abbott Laboratories|$5,475,000    |$0                      |$5,475,000                                               |2013        |20131227    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery   |Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.                                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$1,500,000,000|$0                      |$1,500,000,000                                           |2012        |20120507    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                    |Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.|federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote       |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.             |AbbVie             |$126,500,000  |$0                      |$126,500,000                                             |2010        |20101207    |government-contracting-related offenses|False Claims Act and related                         |null                    |Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.                                                                                                                                                                                                                                                |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases                    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Puerto Rico, Inc.|Abbott Laboratories|$49,045       |$0                      |$49,045                                                  |2009        |20090305    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1527129|null                         |null              |Puerto Rico   |San Juan|null   |null|423450    |423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers|USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php|Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Acclarent Inc.                       |Johnson & Johnson  |$18,000,000   |$0                      |$18,000,000                                              |2016        |20160722    |government-contracting-related offenses|False Claims Act and related                         |null                    |California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.                                                                                                                                                                                                                                                    |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null   |null                         |null              |null          |null    |null   |null|null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+-------------------------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+-------+-----------------------------+------------------+--------------+--------+-------+----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 1</h2>\n<h3> The number of studies in the dataset. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"89d02cb5-44ff-4ff1-aa74-9bfc675a0a0b"}}},{"cell_type":"code","source":["clinical_df.distinct().count()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b15730f1-e577-4a58-9916-e36a55f8ab02"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[7]: 387261","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[7]: 387261"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 2</h2>\n<h3> The types of studies in the dataset and count of each type. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"60ce9767-3d4c-4b85-894e-736f9b7b8d1a"}}},{"cell_type":"code","source":["type_df = clinical_df.groupBy('Type').count().sort('count',ascending=False)\ntype_df.show(5, False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"52877354-524f-47fe-a6fc-b091673608f4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------------------+------+\n|Type                            |count |\n+--------------------------------+------+\n|Interventional                  |301472|\n|Observational                   |77540 |\n|Observational [Patient Registry]|8180  |\n|Expanded Access                 |69    |\n+--------------------------------+------+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------------------+------+\n|Type                            |count |\n+--------------------------------+------+\n|Interventional                  |301472|\n|Observational                   |77540 |\n|Observational [Patient Registry]|8180  |\n|Expanded Access                 |69    |\n+--------------------------------+------+\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 3</h2>\n<h3> The top 5 conditions with their frequency. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"79c7fbbb-cb1b-4c03-b011-bf7840aa7926"}}},{"cell_type":"code","source":["from pyspark.sql import functions as F"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e14cec18-8a98-4814-a0ef-10d433d764eb"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["split_df = clinical_df.withColumn('cond_df', F.split(clinical_df['Conditions'], \",\")).filter(clinical_df['Conditions']!= 'null')\nsd = split_df.withColumn('Disease', F.explode(split_df.cond_df))\nsd.show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e4d9dfc0-d972-4d19-b7bb-2f8b1a7af087"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\n|         Id|             Sponsor|   Status|   Start|Completion|          Type|Submission|          Conditions|Interventions|             cond_df|             Disease|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|         null|[Autistic Disorde...|   Autistic Disorder|\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|         null|[Autistic Disorde...|Autism Spectrum D...|\n|NCT02758483|Universidade Fede...|Completed|Mar 2017|  Jan 2018|Interventional|  Apr 2016|   Diabetes Mellitus|         null| [Diabetes Mellitus]|   Diabetes Mellitus|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|         null|[Tuberculosis, Lu...|        Tuberculosis|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|         null|[Tuberculosis, Lu...|       Lung Diseases|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\n|         Id|             Sponsor|   Status|   Start|Completion|          Type|Submission|          Conditions|Interventions|             cond_df|             Disease|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|         null|[Autistic Disorde...|   Autistic Disorder|\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|         null|[Autistic Disorde...|Autism Spectrum D...|\n|NCT02758483|Universidade Fede...|Completed|Mar 2017|  Jan 2018|Interventional|  Apr 2016|   Diabetes Mellitus|         null| [Diabetes Mellitus]|   Diabetes Mellitus|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|         null|[Tuberculosis, Lu...|        Tuberculosis|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|         null|[Tuberculosis, Lu...|       Lung Diseases|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+-------------+--------------------+--------------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["cond_df = sd.groupby('Disease').agg(F.count('Disease').alias('Condition_freq')).orderBy('Condition_freq', ascending = False)\ncond_df.show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cbb659c1-98cd-45af-a585-85ba8a64ecea"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------------+--------------+\n|          Disease|Condition_freq|\n+-----------------+--------------+\n|        Carcinoma|         13389|\n|Diabetes Mellitus|         11080|\n|        Neoplasms|          9371|\n| Breast Neoplasms|          8640|\n|         Syndrome|          8032|\n+-----------------+--------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------------+--------------+\n|          Disease|Condition_freq|\n+-----------------+--------------+\n|        Carcinoma|         13389|\n|Diabetes Mellitus|         11080|\n|        Neoplasms|          9371|\n| Breast Neoplasms|          8640|\n|         Syndrome|          8032|\n+-----------------+--------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 4</h2>\n<h3> The most frequent roots. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3e6da822-eba6-459e-91bf-02609dc001c9"}}},{"cell_type":"code","source":["split_mesh = mesh_df.join(sd, mesh_df['term'] == sd['Disease'],\"inner\")\nsplit_mesh.withColumn('root', split_mesh['tree'].substr(1, 3))\\\n.select('term', 'root').groupby('root').agg(F.count('root')\\\n.alias('root_freq')).orderBy('root_freq', ascending = False).show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8d3b5cd5-99b5-4db9-b353-31a39c57e6ee"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+---------+\n|root|root_freq|\n+----+---------+\n| C04|   143994|\n| C23|   136079|\n| C01|   106674|\n| C14|    94523|\n| C10|    92310|\n+----+---------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+---------+\n|root|root_freq|\n+----+---------+\n| C04|   143994|\n| C23|   136079|\n| C01|   106674|\n| C14|    94523|\n| C10|    92310|\n+----+---------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 5</h2>\n<h3> The 10 most common sponsors that are not pharmaceutical companies. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"94dc3fab-8417-4123-96e2-2615650cf147"}}},{"cell_type":"code","source":["sponsors_not_pharmas = clinical_df.join(pharma_df, clinical_df['Sponsor'] == pharma_df['Parent_Company'], \"left\")\\\n                       .filter(F.col('Parent_Company').isNull())"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"6e70e922-3ab4-417b-98b1-b6bd559fda5a"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["sponsors_not_pharmas.groupBy('Sponsor').agg(F.count('Sponsor').alias('Sponsor_freq'))\\\n.orderBy('Sponsor_freq', ascending=False).show(10, False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"6e8ceb2f-20db-40f0-b50e-f4c7e443ac4d"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+---------------------------------------+------------+\n|Sponsor                                |Sponsor_freq|\n+---------------------------------------+------------+\n|National Cancer Institute (NCI)        |3218        |\n|M.D. Anderson Cancer Center            |2414        |\n|Assistance Publique - Hôpitaux de Paris|2369        |\n|Mayo Clinic                            |2300        |\n|Merck Sharp & Dohme Corp.              |2243        |\n|Assiut University                      |2154        |\n|Novartis Pharmaceuticals               |2088        |\n|Massachusetts General Hospital         |1971        |\n|Cairo University                       |1928        |\n|Hoffmann-La Roche                      |1828        |\n+---------------------------------------+------------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+---------------------------------------+------------+\n|Sponsor                                |Sponsor_freq|\n+---------------------------------------+------------+\n|National Cancer Institute (NCI)        |3218        |\n|M.D. Anderson Cancer Center            |2414        |\n|Assistance Publique - Hôpitaux de Paris|2369        |\n|Mayo Clinic                            |2300        |\n|Merck Sharp & Dohme Corp.              |2243        |\n|Assiut University                      |2154        |\n|Novartis Pharmaceuticals               |2088        |\n|Massachusetts General Hospital         |1971        |\n|Cairo University                       |1928        |\n|Hoffmann-La Roche                      |1828        |\n+---------------------------------------+------------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Question 6</h2>\n<h3> The number of completed studies each month in a given year. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ebfdb1e5-9bf7-4ed8-99c1-25049a8b9105"}}},{"cell_type":"code","source":["year = fileroot[14:18]\ntr = clinical_df.filter((clinical_df['Completion']).contains (year))\\\n     .filter( (clinical_df['status'] == 'Completed')).select('Completion')\\\n     .groupBy('Completion').count()\n\nstudies_df = tr.withColumn('month', tr['Completion'].substr(1, 3)).select('month', 'count')\nstudies_df.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"55425e1a-9ffb-4d24-a7fd-82754db8a750"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----+-----+\n|month|count|\n+-----+-----+\n|  Mar| 1227|\n|  Sep|  528|\n|  May|  984|\n|  Oct|  187|\n|  Jun| 1094|\n|  Feb|  934|\n|  Aug|  700|\n|  Jan| 1131|\n|  Jul|  819|\n|  Apr|  967|\n+-----+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----+-----+\n|month|count|\n+-----+-----+\n|  Mar| 1227|\n|  Sep|  528|\n|  May|  984|\n|  Oct|  187|\n|  Jun| 1094|\n|  Feb|  934|\n|  Aug|  700|\n|  Jan| 1131|\n|  Jul|  819|\n|  Apr|  967|\n+-----+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["for row in studies_df:\n    st_df = dict(studies_df.collect())\nmonths = ['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct']\ne_list = []\nfor m in months:\n    st = (m, st_df[m])\n    e_list.append(st)\nprint(e_list)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5f529453-e831-4170-8a1a-a87a9c8aec85"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"[('Jan', 1131), ('Feb', 934), ('Mar', 1227), ('Apr', 967), ('May', 984), ('Jun', 1094), ('Jul', 819), ('Aug', 700), ('Sep', 528), ('Oct', 187)]\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["[('Jan', 1131), ('Feb', 934), ('Mar', 1227), ('Apr', 967), ('May', 984), ('Jun', 1094), ('Jul', 819), ('Aug', 700), ('Sep', 528), ('Oct', 187)]\n"]}}],"execution_count":0},{"cell_type":"code","source":["list_df = spark.sparkContext.parallelize(e_list)\nmonth_df = spark.createDataFrame(list_df)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"0799e88b-5054-4a4a-b4d5-1eb037556158"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["studies_df = month_df.withColumnRenamed(\"_1\",\"Month\")\\\n             .withColumnRenamed(\"_2\",\"count\")\nstudies_df.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"dcef9ad3-8d6f-4ba2-9cb1-9e7931c8d410"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----+-----+\n|Month|count|\n+-----+-----+\n|  Jan| 1131|\n|  Feb|  934|\n|  Mar| 1227|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jul|  819|\n|  Aug|  700|\n|  Sep|  528|\n|  Oct|  187|\n+-----+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----+-----+\n|Month|count|\n+-----+-----+\n|  Jan| 1131|\n|  Feb|  934|\n|  Mar| 1227|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jul|  819|\n|  Aug|  700|\n|  Sep|  528|\n|  Oct|  187|\n+-----+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import seaborn as sns\nsns.set_style('darkgrid')\nsns.barplot(data=studies_df.toPandas(), x=\"Month\", y=\"count\",color='steelblue', order = months )"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5d19545a-f85e-4182-9f69-a8559ae09116"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[19]: <AxesSubplot:xlabel='Month', ylabel='count'>","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[19]: <AxesSubplot:xlabel='Month', ylabel='count'>"]}},{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["<h2> Further analysis</h2>\n<h3> The number of offenses in a given year. </h3>"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8c356148-9dce-4968-a0de-ce67cdee3b7d"}}},{"cell_type":"code","source":["offense_df = pharma_df.filter((pharma_df['Penalty_Year']).contains(year))\\\n         .groupBy('Offense_Group').count().orderBy('count', ascending=False)\n\noffense_df.show(5, False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f953a925-797f-4b5d-98e5-fcaccc3d98b9"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+---------------------------------------+-----+\n|Offense_Group                          |count|\n+---------------------------------------+-----+\n|healthcare-related offenses            |4    |\n|government-contracting-related offenses|4    |\n|environment-related offenses           |2    |\n|safety-related offenses                |2    |\n|employment-related offenses            |1    |\n+---------------------------------------+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+---------------------------------------+-----+\n|Offense_Group                          |count|\n+---------------------------------------+-----+\n|healthcare-related offenses            |4    |\n|government-contracting-related offenses|4    |\n|environment-related offenses           |2    |\n|safety-related offenses                |2    |\n|employment-related offenses            |1    |\n+---------------------------------------+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":[""],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7c2895d3-9a02-4468-a238-b1063a504a10"}},"outputs":[],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"Ogbebor_Dataframe","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":3186316683966100}},"nbformat":4,"nbformat_minor":0}
